Mackenzie Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

Mackenzie Financial’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.12M	Buy	+280,079	New	+$5.82M	0.01%	783

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Mackenzie Financial's SNDX Position: Q2 2026 in Review

Mackenzie Financial opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 280,079 shares worth $6.12M. The stake represents 0.01% of the portfolio and ranks #783 among its holdings.

242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Mackenzie Financial held 280,079 shares of Syndax Pharmaceuticals worth $6.12M as of Q2 2026.
Syndax Pharmaceuticals was a new Mackenzie Financial position in Q2 2026.
Syndax Pharmaceuticals made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #783 holding.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.